Good morning :)
$
₹
iBio, Inc. Common Stock

iBio, Inc. Common Stock

IBIO

NASDAQ
Asset Logo

iBio, Inc. Common Stock

IBIO

NASDAQ
$0.710.80% (-0.00)
$
₹
$0.710.80% (-0.00)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Micro Cap

With a market cap of $35.7M the stock is ranked 5029

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

0.88
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-0.32
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

0
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 9 analysts reports

Buy
9 analysts
Hold
0 analyst
Sell
0 analyst

Price Upside

+692.55%

Earnings Growth

+22.49%

Rev. Growth

-75%

See Detailed Forecast

Company Profile

Company Profile

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large target proteins Its product pipelines for cardiometabolic disease area include IBIO-601, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody designed to inhibit myostatin and activin A signaling to preserve lean mass; IBIO-600 Myostatin Antibody, monoclonal antibody blocking myostatin that is in phase 1; Amylin Antibody, a pancreatic hormone that promotes satiety and appetite control through activation of the amylin receptor; CCR8, a Treg-targeting immunotherapy; and MUC16 antibodies. In addition, the company is developing, an antibody therapeutics to treat glioblastoma and other cancers by selectively killing EGFRvIII tumor cells without destroying healthy tissue; and TROP-2 x CD3 bispecific antibody that is developed with EngageTx platform to harness T cells to kill TROP-2"expressing tumors while minimizing the cytokine release that often limits the tolerability of T-cell engagers. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. The company was formerly known as iBioPharma, Inc. and changed its name to iBio, Inc. in August 2009. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large target proteins Its product pipelines for cardiometabolic disease area include IBIO-601, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody designed to inhibit myostatin and activin A signaling to preserve lean mass; IBIO-600 Myostatin Antibody, monoclonal antibody blocking myostatin that is in phase 1; Amylin Antibody, a pancreatic hormone that promotes satiety and appetite control through activation of the amylin receptor; CCR8, a Treg-targeting immunotherapy; and MUC16 antibodies. In addition, the company is developing, an antibody therapeutics to treat glioblastoma and other cancers by selectively killing EGFRvIII tumor cells without destroying healthy tissue; and TROP-2 x CD3 bispecific antibody that is developed with EngageTx platform to harness T cells to kill TROP-2"expressing tumors while minimizing the cytokine release that often limits the tolerability of T-cell engagers. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. The company was formerly known as iBioPharma, Inc. and changed its name to iBio, Inc. in August 2009. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
80.68
80.68
1Y Return
24.94%
24.94%
Buy Reco %
80.00
80.00
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
27.28
27.28
1Y Return
51.04%
51.04%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
29.23%
29.23%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
29.90
29.90
1Y Return
23.96%
23.96%
Buy Reco %
81.25
81.25
Moderna Inc
MRNA
Moderna Inc
P/E Ratio
—
—
1Y Return
662.28%
662.28%
Buy Reco %
21.73
21.73
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 692.55% growth, versus a trailing 3-year CAGR of -50.73%.

2026
Current$0.72Baseline
Analyst Target - 1 year
Target$5.69+692.55%

All values in $

202220232024202520262027$2.91$5.16$7.42Target+692.55%
2026
Current$0.72Baseline
Analyst Target - 1 year
Target$5.69+692.55%

All values in $

Revenue Forecast

Revenue Forecast

Lower revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies -75.00% growth, versus a trailing 3-year CAGR of 25.99%.

2026
Current$0.1Baseline
Forecast for Jun 2027
High$0.1+0%
Average$0.02-75%
Low$0-100%

All values in $ Million

2022202320242025202620271.880.050.220.40.1Low-100%Average-75%High-0%
2026
Current$0.1Baseline
Forecast for Jun 2027
High$0.1+0%
Average$0.02-75%
Low$0-100%

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

2026
Current$-0.48Baseline
Forecast for Jun 2027
High$-0.22+54.6%
Average$-0.38+22.49%
Low$-0.85-75.4%

All values in $

202220232024202520262027-57.96-147-6.42-1.75-0.48Low-75.4%Average+22.49%High+54.6%
2026
Current$-0.48Baseline
Forecast for Jun 2027
High$-0.22+54.6%
Average$-0.38+22.49%
Low$-0.85-75.4%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

0.1
-5.7
-8.9
-7.7
-10.6
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue00.1700.200.20.1000
Net Income-3.17-7.77-3.98-4.36-4.86-5.16-5.72-8.99-7.73-10.60
Net Profit Margin--4444.57%--2182%--2581.5%-5720%---
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
iBio, Inc. Common Stock -0.880
AbbVie Inc80.6850.450.53
Amgen Inc27.2817.562.28
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare IBIO with any stock or ETF
Compare IBIO with any stock or ETF
Comparing from
IBIO
ABBV
AMGN
Loading...

Frequently asked questions

  1. iBio, Inc. Common Stock (IBIO) share price today is $0.71 as of October 27, 2026 at 12:04 AM IST. The stock touched a day high of $0.73 and a day low of $0.69.

  2. iBio, Inc. Common Stock stock trades on NASDAQ under the ticker symbol IBIO.

  3. iBio, Inc. Common Stock's market capitalization is $35.65M as of October 27, 2026 at 12:04 AM IST.

  4. iBio, Inc. Common Stock's price-to-earnings (P/E) ratio is N/A as of October 26, 2026.

  5. iBio, Inc. Common Stock's price-to-book (P/B) ratio is 0.88 as of October 26, 2026.

  6. Yes, You can buy iBio, Inc. Common Stock shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy iBio, Inc. Common Stock shares in three steps: 1. Search iBio, Inc. Common Stock on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since iBio, Inc. Common Stock trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in iBio, Inc. Common Stock (IBIO) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 14.0449 shares at the current price of $0.71.

Loading...